Esha Chakravarty
*
Mehmet T. Dorak
*The final, formatted version of the article will be published soon.
OPINION article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1443726
Missed opportunities to increase efficiency of monoclonal antibody development using hybridoma technology and mice as the source animal
Provisionally accepted- Kingston University, Kingston upon Thames, England, United Kingdom
Keywords: Monoclonal antibody development, Mice, inbred, BALB/c, hybridoma, Histocompatibility, MHC restriction, Antigen Presentation, Th2 immune response
Received: 04 Jun 2024; Accepted: 25 Jul 2024.
Copyright: © 2024 Chakravarty and Dorak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Esha Chakravarty, Kingston University, Kingston upon Thames, KT1 1LQ, England, United Kingdom
Mehmet T. Dorak, Kingston University, Kingston upon Thames, KT1 1LQ, England, United Kingdom
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.